RxDoctor Payments Data

James Morris, MD

Urology · Baton Rouge, LANPI 1043271497

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.5% of the total across 427 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations.

$7,540in general payments, 2019–2025

Across 427 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Antares Pharma, Inc.$832
  • Astellas Pharma US Inc$804
  • Johnson & Johnson$566
  • Bayer$506
  • Boston Scientific$449
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,12995%
  • Education$4115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,540 in reported general payments places this provider in the 75th percentile of 199 urology providers in Louisiana.

See all urology providers in Louisiana

Medicare billing

Part B allowed, 2024
$500,017
Medicare patients
921
Services billed
18,708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide29$339,134
MyrbetriqMirabegron459$279,556
GemtesaVibegron224$123,738
Testosterone86$22,313
XyostedTestosterone Enanthate14$8,369
Mirabegron ErMirabegron16$7,482
NitrofurantoinNitrofurantoin Macrocrystal242$5,489
Testosterone Cypionate177$5,170
Cephalexin723$5,150
Tamsulosin Hcl482$4,733
Bethanechol Chloride84$4,438
Trimethoprim86$3,459
Dutasteride123$3,222
Imipramine Pamoate16$2,789
Imipramine Hcl173$2,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$804$618,690488 claims
Sumitomo Pharma America, Inc.Gemtesa$161$123,738224 claims
Antares Pharma, Inc.Xyosted$832$8,36914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 199 urology providers in Louisiana.

Other urology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →